28 January 2026 : Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers
Halil Göksel Güzel
ABCDEF 1*, Arif Hakan Önder ABDEF 1, Yusuf İlhan BD 2, Onur Yazdan Balçık BD 3, Banu Öztürk ABEF 1
DOI: 10.12659/MSM.951027
Med Sci Monit 2026; 32:e951027
Table 2 Comparison of general health insurance–based public hospitals and private hospitals.
| Public hospitals (n=63) | Private hospitals (n=23) | P value | |
|---|---|---|---|
| 1 (0–50) | 2 (0–50) | 0.961 | |
| 0.086 | |||
| 0 (0–42) | 0 (0–30) | 0.862 | |
| 2 (0–6) | 1 (0–5) | 0.203 | |
| 0.069 | |||
| Yes, easily | 27 (46.6) | 18 (78.3) | |
| Sometimes, hardly | 24 (41.4) | 4 (17.4) | |
| No, Never | 4 (6.9) | 1 (4.3) | |
| Not answered | 3 (5.2) | 0 (0.0) | |
| 0.371 | |||
| Breast cancer | 16 (25.8) | 4 (17.4) | |
| Lung cancer | 24 (38.7) | 15 (65.2) | |
| Gastrointestinal cancers | 4 (6.5) | 1 (4.3) | |
| Prostate-urinary bladder cancer | 6 (9.7) | 1 (4.3) | |
| Renal cell carcinoma | 0 (0.0) | 0 (0.0) | |
| Melanoma | 1 (1.6) | 1 (4.3) | |
| Other | 1 (1.6) | 0 (0.0) | |
| Unable to reach any clinical trials | 10 (16.1) | 1 (4.3) | |
| Not answered | 1 (1.6) | 0 (0.0) | |
| 0.108 | |||
| NGS available | 24 (38.1) | 12 (52.2) | |
| NGS unavailable but reachable | 29 (46.0) | 11 (47.8) | |
| NGS unavailable and unreachable | 10 (15.9) | 0 (0.0) | |
| NGS – next-generation sequencing. | |||